Managing emerging mutagenicity risks: Late stage mutagenic impurity control within the atovaquone second generation synthesis
- 15 August 2018
- journal article
- research article
- Published by Elsevier BV in Regulatory Toxicology and Pharmacology
- Vol. 99, 22-32
- https://doi.org/10.1016/j.yrtph.2018.08.004
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Potential impurities in drug substances: Compound-specific toxicology limits for 20 synthetic reagents and by-products, and a class-specific toxicology limit for alkyl bromidesRegulatory Toxicology and Pharmacology, 2018
- A consortium-driven framework to guide the implementation of ICH M7 Option 4 control strategiesRegulatory Toxicology and Pharmacology, 2017
- Mutagenicity assessment strategy for pharmaceutical intermediates to aid limit setting for occupational exposureRegulatory Toxicology and Pharmacology, 2015
- Do Carboxylic/Sulfonic Acid Halides Really Present a Mutagenic and Carcinogenic Risk as Impurities in Final Drug Products?Organic Process Research & Development, 2015
- ICH Q11: development and manufacture of drug substances–chemical and biotechnological/biological entitiesGenerics and Biosimilars Initiative Journal, 2012
- In silico methods combined with expert knowledge rule out mutagenic potential of pharmaceutical impurities: An industry surveyRegulatory Toxicology and Pharmacology, 2012
- Approaches to Assessment, Testing Decisions, and Analytical Determination of Genotoxic Impurities in Drug SubstancesOrganic Process Research & Development, 2008
- Über die Darstellung von δ‐LactonenEuropean Journal of Inorganic Chemistry, 1961
- Eine neue Methode zur Darstellung langkettiger Carbonsäuren, I. Mitteil.: Darstellung einiger einfacher Mono‐und DicarbonsäurenEuropean Journal of Inorganic Chemistry, 1952
- ALCOHOLYSIS AND HYDROLYSIS OF 1,3-DIKETONES AND BETA-KETO ESTERSJournal of the American Chemical Society, 1932